Recording of live webinar presented on August 16, 2012

A certified one-hour prerecorded webinar case review for radiologists, interventional radiologists, hepatologists, oncologists, surgeons, and other subspecialists who treat and manage patients with liver disease.
 

Format:        Archived Webinar
MD Credit:  1.0 AMA PRA Category 1

This course will expire as of October 1, 2018.  This expiration date cannot be extended.

If you want credit, the course must be completed (i.e. view the recording, pass the posttest, AND print the certificate) by no later than September 30^th, 2018.

Please note, after this course has expired, no aspect of the course will be accessible, including the recorded lecture.

Course Overview
Primary liver cancer is a leading cause of cancer deaths worldwide. The American Cancer Society projects an estimated 18,910 liver cancer deaths and 24,120 new cases of liver cancer in 2010. The five-year relative survival rate for patients with liver cancer is 14% [1]. The integrity of data collection of imaging findings and outcome monitoring of HCC across the country is compromised by the lack of standardized criteria for stratification of lesions and consistent reporting terminology and content [2, 3]. Given the magnitude and severity of HCC, there is a need for a standardized reporting system for CT and MR imaging surveillance and staging of HCC in patients.

In March 2011, the ACR adopted the Liver Imaging Reporting and Data System (LI-RADS®) as a universal method for categorizing liver findings in patients with end stage liver disease. The production of CT-MR LI-RADS categories will [2, 3, 4]:

• Reduce the frequency of technically inadequate examinations by specifying minimum acceptable technical parameters for CT and MR surveillance imaging procedures
• Improve communication with clinicians, reduce variability in lesion interpretation, and facilitate meta-analysis of published manuscripts by creating a lexicon of controlled CT and MR terminology
• Reduce omissions of relevant information from CT and MR reports by standardizing report content and structure, and
• Facilitate outcome monitoring, performance auditing, quality assurance, and research by producing a formal data collection system

This activity will introduce the learner to the LI-RADS system and provide case examples which illustrate the concepts and lexicon recommended by the LI-RADS committee.

[1] American Cancer Society Web page:  Cancer Facts and Figures 2010.  Available at:  http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf  Accessed December 9, 2011.
[2] American College of Radiology. ACR Creates LI-RADS Committee to Standardize Reporting for HCC. Available at http://www.acr.org/MainMenuCategories/media_room/FeaturedCategories/PressReleases/Archive/ACRCreatesLIRADSCommittee.aspx. Accessed on December 8, 2011.
[3] American College of Radiology. LI-RADS Concepts: Conceptual Descriptions of Categories. Available at http://www.acr.org/SecondaryMainMenuCategories/quality_safety/LI-RADS/LiRads-Definitions.aspx. Accessed on December 8, 2011. American College of Radiology.
[4] American College of Radiology. LI-RADS Lexicon Terms. http://www.acr.org/SecondaryMainMenuCategories/quality_safety/LI-RADS/Lexicon-Terms.aspx. Accessed on December 8, 2011.

Educational Objectives
At the conclusion of this activity, participants should be better able to:

• Describe the need for a standardized reporting system for CT and MR imaging surveillance and staging for hepatocellular carcinoma (HCC) in patients with cirrhosis

• Identify the Liver Imaging Report and Data System (LI-RADS®) criteria and categories

• Apply LI-RADS criteria and categories to CT and MRI liver images

Accreditation & Credit
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Physicians
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

SA-CME: This activity meets the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology (ABR) Maintenance of Certification Program.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information go to http://www.uems.eu/uems-activities/accreditation/eaccme.

How to Enroll and Participate
There are no fees or prerequisites to participate in this program. Estimated time to complete this activity is one hour.

• Click ENROLL NOW, CONTINUE, CONFIRM ORDER, and ACCESS COURSE NOW.
• Click on the blue link. Complete the precourse questions and SUBMIT.
• Click on the blue link again to view the recording.

How to Receive a Credit Certificate
Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.

• Log-in to your account at www.icpme.us
• View the entire educational activity session. At the conclusion of the lecture, close the recording window.
• Return to the course in your account at www.icpme.us.
• From the COURSE HOME page, click the button for POSTTEST and for EVALUATION.
• A passing grade of at least 75% is required to receive credit. You may take the test up to three times.
• Upon receipt of a passing grade, you will be able to print a certificate of credit from your account at www.icpme.us

Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.

Faculty Biographies

Cynthia S. Santillan, MD
Dr. Santillan did her undergraduate studies at Massachusetts Institute of Technology and Washington University School of Medicine.  Following an internship at Forest Park Hospital in St. Louis, Dr. Santillan went on to complete her residency in diagnostic radiology at Mallinckrodt Institute of Radiology – Washington University School of Medicine and a fellowship in body imaging at University of California, San Diego (UCSD).

Currently Dr. Santillan is Associate Professor of Radiology, Vice Chief of Body Imaging, and Chief of Body Computed Tomography at UCSD. Since 2007, she has been an invited speaker at many medical society meetings including those hosted by the American Roentgen Ray Society.  She is a member of the Liver Imaging Reporting and Data System (LI-RADS) Committee for the American College of Radiology (ACR).  Dr. Santillan has co-authored many publications and her educational exhibits at international society meetings have won Cum Laude Awards and Certificates of Merit.

Claude B. Sirlin, MD
Dr. Sirlin received his undergraduate degree from Harvard University and his medical degree from University of California, San Francisco.  He completed residency training in diagnostic radiology at University of California, San Diego (UCSD) and fellowship training in cross-sectional body imaging (MR, CT, US) at Stanford University. He joined the faculty at UCSD in 2001. Currently Dr. Sirlin is Associate Professor of Radiology, Chief of Body Imaging, Chief of Abdominal MRI and Director of the Liver Imaging Group.

Dr. Sirlin chairs the Liver Imaging Reporting and Data System (LI-RADS) Committee for the American College of Radiology (ACR) and is chair of the Radiology Committee for the NIH-funded Non-Alcoholic  Steatohepatitis Clinical Research Network.

Dr. Sirlin’s research focuses on MR imaging of liver cancer and diffuse liver disease.  He has published many papers, book chapters, scientific abstracts, educational exhibits, and reviews for several scientific journals.  Dr. Sirlin is a dedicated teacher and mentor to undergraduates, medical students, residents and fellows in clinical imaging research at UCSD.

Disclosure Information
The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty below reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Cynthia S. Santillan, MD has reported no financial relationships with commercial interests.

Claude B. Sirlin, MD has received fees for contracted research, consulting and for non-CME services from Bayer HealthCare Pharmaceuticals and fees for contracted research from General Electric.

The planners and managers below reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Sharon Cancino
Laura Excell, ND, NP, MS, MA, LPC, NCC
Trace Hutchison, PharmD
Samantha Mattiucci, PharmD
Linda McLean, MS
Victoria Phoenix, BS
Lisa Schleelein, MEd
Patricia Staples, MSN, NP-C, CCRN

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, ICPME and Bayer HealthCare Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the view of PIM, ICPME and Bayer HealthCare Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Questions
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860

JOINTLY PROVIDED BY

               


SUPPORTED BY AN INDEPENDENT EDUCATIONAL GRANT FROM  BAYER HEALTHCARE

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.